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Objective: We sought to evaluate the safety and efficacy of the first available totally
implantable replacement heart (AbioCor Implantable Replacement Heart System) in
the treatment of severe, irreversible biventricular heart failure in human patients.
Methods: Seven male adult patients with severe, irreversible biventricular failure
(70% thirty-day predicted mortality) who were not candidates for transplantation
met all institutional review board study criteria and had placement of the AbioCor
Implantable Replacement Heart. All were in cardiogenic shock despite maximal
medical therapy, including inotropes and intra-aortic balloon pumps. Mean age was
66.7  10.4 years (range, 51-79 years). Four of 7 patients had prior operations. Six
had ischemic and one had idiopathic cardiomyopathy. All had 3-dimensional
computer-simulated implantation of the thoracic unit that predicted adequate fit. At
the time of the operation, the internal transcutaneous energy transfer coil, battery,
and controller were placed. Biventriculectomy was then performed, and the thoracic
unit was placed in an orthotopic position and attached to the atrial cuffs and outflow
conduits with quick-connects. The flow was adjusted to 4 to 8 L/min. Central venous
and left atrial pressures were maintained at 5 to 15 mm Hg. The device is powered
through transcutaneous energy transfer. An atrial flow-balancing chamber is used to
adjust left/right balance. The balance chamber and transcutaneous energy transfer
eliminate the need for percutaneous lines.
Results: There was one intraoperative death caused by coagulopathic bleeding and
one early death caused by an aprotinin reaction. There have been multiple morbid-
ities primarily related to preexisting illness severity: 5 patients had prolonged
intubation, 2 had hepatic failure (resolved in 1), 4 had renal failure (resolved in 3),
and 1 each had recurrent gastrointestinal bleeding, acute cholecystitis requiring
laparotomy, respiratory failure that resolved after 3 days of extracorporeal mem-
brane oxygenation, and malignant hyperthermia (resolved). There were 3 late
deaths: one caused by multiple systems organ failure (postoperative day 56), one
caused by a cerebrovascular accident (postoperative day 142), and one caused by
retroperitoneal bleeding and resultant multiple systems organ failure (postoperative
From the Department of Surgery,a Division
of Thoracic and Cardiovascular Surgery,
University of Louisville School of Medi-
cine, Louisville, Ky; the Division of Car-
diothoracic Surgery,b University of Califor-
nia Los Angeles School of Medicine, Los
Angeles, Calif; the Division of Cardiotho-
racic Surgery,c MCP Hahnemann Univer-
sity, Philadelphia, Pa; the Division of Car-
diothoracic Surgery,d Texas Heart Institute
Medical Center, Houston, Tex; and the Di-
vision of Cardiac Surgery,e Massachusetts
General/Brigham & Women’s Hospital,
Boston, Mass.
Received for publication May 14, 2002;
revisions requested July 12, 2002; revisions
received July 25, 2003; accepted for publi-
cation July 30, 2003.
Address for reprints: Robert D. Dowling,
MD, 201 Abraham Flexner Way, #1200,
Louisville, KY 40202 (E-mail: rdowling@
ucsamd.com or jwalsh@ucsamd.com).
J Thorac Cardiovasc Surg 2004;127:131-41
0022-5223/$30.00
Copyright © 2004 by The American Asso-
ciation for Thoracic Surgery
doi:10.1016/j.jtcvs.2003.07.023
The Journal of Thoracic and Cardiovascular Surgery ● Volume 127, Number 1 131
A
CD
day 151). This latter patient was not able to tolerate anticoagulation (no anticoag-
ulation or antiplatelet therapy alone for 80% of the first 60 days) and had a transient
ischemic attack on postoperative day 61 and a cerebrovascular accident on postop-
erative day 130. At autopsy, blood pumps were clean. The 2 patients who had large
cerebrovascular accidents had thrombus on the atrial cage struts. These struts have
been removed for future implants. There has been no significant hemolysis or
device-related infections. The balance chamber has allowed for left/right balance in
all patients (left atrial pressure within 5 mm Hg of right atrial pressure). Three
patients have taken multiple (50) trips out of the hospital, and 2 have been
discharged from the hospital. Total days on support with the AbioCor are 759.
Conclusion: The initial clinical experience suggests that the AbioCor might be
effective therapy in patients with advanced biventricular failure. There have been no
significant device malfunctions. Two of these patients have been discharged from
the hospital.
The prevalence of heart failure continues toincrease, and current estimates are that heartfailure affects nearly 5 million people in theUnited States and 15 million people world-wide.1 Despite improvements in medicalmanagement, 5-year survival remains less
than 50% for all patients with heart failure.1,2 A recent
population-based study demonstrated that survival after the
first hospital admission for heart failure was worse than
survival for all common malignancies except lung cancer.3
A significant portion of patients with end-stage heart failure
could benefit from some type of cardiac replacement ther-
apy. Currently, heart transplantation is the only approved
method for replacing the failing heart. However, there is a
severe shortage of donor organs, with only 2198 heart
transplantations being performed in the United States in the
year 2000.4 Furthermore, in 3 of the last 4 years, there has
been a decrease in the number of heart transplantations
performed in the United States.
The AbioCor Implantable Replacement Heart (IRH) sys-
tem has been under development for more than 2 decades.5-9
This system is the first implantable artificial heart system
approved for clinical trials that does not require percutane-
ous lines. From inception, the device has been designed as
destination therapy. A major focus of the device design, in
addition to allowing for prolonged life, has been to allow for
an acceptable quality of life. Initial animal experience and
development was performed by ABIOMED (Danvers,
Mass) and the team at the Texas Heart Institute, with
funding from the National Heart, Lung, and Blood Institute.
Subsequent preclinical implantations were also performed
at the University of Louisville under Good Laboratory Prac-
tice guidelines. Successful preclinical implantations and
reliability studies resulted in US Food and Drug Adminis-
tration approval for a multicenter trial. We report the early
human experience with the AbioCor IRH System as desti-
nation therapy.
Methods
Device Description
The AbioCor IRH System is the first artificial heart system that
does not require percutaneous lines or percutaneous access. This
system consists of both external and internal components. The 4
internal components are the AbioCor thoracic unit, the battery, the
controller, and the transcutaneous energy transfer (TET) coil (Fig-
ure 1). The AbioCor thoracic unit is placed in the chest in an
orthotopic position after excision of the native ventricles. The
thoracic unit consists of an energy converter and 2 pumping
chambers that function as the left and right ventricles. The energy
converter is situated between the ventricles and contains a high-
efficiency miniature centrifugal pump driven by a brushless direct
current motor. The motor speed of this pump can vary to account
for the different resistances of the systemic and pulmonary vascu-
lar systems and systolic ejection durations. This centrifugal pump
operates unidirectionally to pressurize a low-viscosity hydraulic
fluid. A 2-position switching valve is used to alternate the direction
of hydraulic flow between the left and right pumping chambers.
This results in alternate left and right systole. The rate of the
switching valve determines the beat rate of the device and can be
varied between 75 and 150 beats/min, resulting in a range of flows
from 4 to 8 L/min. There is a one-to-one correspondence between
blood and hydraulic fluid displacement. The displacement of hy-
draulic fluid to one side results in the creation of a negative
pressure in the opposite ventricle. Thus the device is considered an
active fill device. An atrial balance chamber is present and allows
for decreased right-sided stroke volume to maintain right and left
fluid balance.8,9 Essentially, a portion of hydraulic fluid is shunted
into the balance chamber rather than to the right hydraulic pump-
ing chamber. The amount of fluid that is shunted into the balance
chamber can be adjusted manually or automatically on the basis of
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the relative left and right filling pressures. The pump motor im-
peller and the switching valve are the major moving parts of the
energy converter. All blood-contacting surfaces of the AbioCor
thoracic unit, including the trileaflet valves (24-mm internal diam-
eter), are made of polyetherurethane (Angioflex), resulting in a
smooth, continuous, blood-contacting surface from the inflow
cuffs to the outflow grafts.
The internal battery is lithium ion based and is able to power
the thoracic unit for brief (up to 20 minutes) periods of time. The
internal controller drives the energy converter in the thoracic unit,
monitors the implanted components, and transmits device perfor-
mance data to a bedside console by means of radiofrequency
telemetry. These radiofrequency transmissions from the internal
controller to the external console convey information, including
continuous real-time telemetry of hydraulic pressure waveforms,
system operating parameters, battery status, component tempera-
ture, and alarm information. This information is stored for later
retrieval and analysis. The internal TET coil receives high-fre-
quency power that is transmitted across the skin from the external
TET coil. The internal TET system electronics convert this oscil-
lating current to a direct current that is used to power the thoracic
unit and to recharge the internal battery. Dacron velour (E.I.
duPont de Nemours) atrial cuffs are sutured to the native left and
right annuli and attached to the thoracic unit by means of snap-lock
connectors. In the first 6 recipients, the atrial cuffs incorporated 2
curved intersecting plastic struts that were developed during ani-
mal trials to prevent collapse of the small bovine native atria that
can lead to inflow obstruction to the thoracic unit (Figure 2). The
outflow grafts are 32-mm, coated, woven Dacron grafts with 8-mm
side ports that are used for deairing.
The 4 external components consist of an external TET coil,
batteries, a TET module, and a bedside console (Figure 3). The
external TET coil transfers energy across the skin to the internal
TET coil and is secured over the internal TET coil with an
adhesive dressing.10 The external TET coil can be connected to
either the bedside console or a portable TET module. The bedside
console is used during implantation, recovery, and when the pa-
tient is in his or her primary residence. The bedside console
provides clinicians with a graphic user interface for control and
Figure 2. Atrial cuff with struts. Future implants will be per-
formed with atrial cuffs that do not have these struts.
Figure 1. Internal components of the AbioCor IRH include the thoracic unit, controller, battery, and TET coil.
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monitoring of the implanted system through radiofrequency com-
munication. The console can be configured to operate in different
modes for implantation, recovery, and home monitoring. The
console can be remotely monitored when connected to a telephone
jack through a laptop computer. A rechargeable battery in the
console allows it to be disconnected from AC power for brief
periods without discharging the patient’s internal battery. When
the patient is ambulatory, the external TET coil is connected to the
portable TET module. The TET module delivers energy to the TET
coil from external batteries and contains basic alarm systems that
are activated if there is misalignment of the TET coil, low external
battery voltage, or a general alarm indicating a potential problem
with the system that is determined by reestablishing radiofre-
quency communication with the bedside console. The external
batteries are lithium ion based and are able to provide up to 1 hour
of support per pound of battery. The external batteries can either be
carried in a vest or a handbag or attached to a Velcro belt.
Clinical Trial Design
US Food and Drug Administration approval for initiation of a
multicenter clinical trial was granted in January 2001. The original
centers were Hahnemann University, Massachusetts General Hos-
pital/Brigham and Women’s Hospital, the Texas Heart Institute,
the University of California Los Angeles, and the University of
Louisville. The University of Arizona Medical Center has recently
been added as an investigational center. The AbioCor IRH is
intended for use as destination therapy. Therefore patients selected
for this clinical trial were not candidates for other types of therapy,
including heart transplantation. All patients who are considered as
candidates have a 30-day predicted mortality of greater than 70%
on the basis of the AbioScore prognostic model or acute myocar-
dial infarction shock scores.11 The AbioScore mortality prediction
model was developed on the basis of previous prognostic models,
with selection of parameters that had the highest prognostic value
for mortality in patients with end-stage heart failure. Initial retro-
spective studies were followed by prospective studies that verified
that this was an accurate prediction model. These variables are
shown in Table 1. The AbioScore model is used to exclude patients
who have a greater than 30% one-month survival.12
Potential candidates must be adult patients with biventricular
failure who are receiving maximal medical therapy and who are
dependent on inotropes or unable to tolerate inotropes because of
severe arrhythmias. Patients are excluded from the study if they are
candidates for other conventional therapies, including heart trans-
plantation, or if they have a predicted survival of greater than 30%
at 30 days. Other exclusion criteria include end-organ dysfunction
that is believed by the clinicians to not be reversible, active
infection, severe peripheral vascular disease, blood dyscrasia, and
recent stroke or transient ischemic attack caused by atherosclerotic
disease. A complete psychosocial evaluation is performed on all
potential recipients similar to that performed with patients being
considered for transplantation. Patients meeting the appropriate
criteria undergo computed tomographic scanning of the chest,
followed by a virtual fit evaluation. A 3-dimensional computerized
image of the AbioCor thoracic unit is superimposed on the image
of the patient’s mediastinal and chest wall structures derived from
the computed tomographic scan. This computer simulation dem-
onstrates the position and fit of the thoracic unit in a potential
recipient’s chest. This virtual model allows one to determine
whether the AbioCor thoracic unit can be positioned in the chest
without impinging on vital structures, such as the left pulmonary
veins and the left lower lobe bronchus. The surgical implant team
must have a high degree of certainty that the AbioCor thoracic unit
will fit in the chest before proceeding with operative implantation.
During this extensive evaluation, the patient and his or her family
receives intensive education on the device, including the results of
reliability studies, preclinical trials, and previous human implan-
tations.
The institutional review board at each of the institutions ap-
proved the clinical protocol. For every patient who enters or
Figure 3. External components displaying the portable TET module and external batteries attached to a Velcro belt.
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considers entering the AbioCor clinical trial, an independent pa-
tient advocate is made available to them and their families to assist
in the understanding of the potential risks and benefits of entering
the clinical trial.13 The patient advocate is able to help the patient
and his or her family to interpret the contents of the informed
consent document. After the implantation procedure, the patient
advocate continues to be available to the patient and family for
assistance in making other important medical decisions. Each
patient advocate has a background in clinical medicine and func-
tions completely independently of both the sponsoring company
and the medical teams.
The primary end point of this trial is to determine the effect of
the AbioCor on all causes of mortality in patients with severe heart
failure and predicted life expectancy of less than 30 days despite
optimized medical management. Secondary end points include
determination of adverse events, device malfunctions, or compli-
cations related to the presence of the device and quality of life.
Operative Approach
At operation, an infraclavicular incision is made, and a pocket is
created anterior to the pectoral muscle fascia for placement of the
internal TET coil. A median sternotomy incision is then made. The
internal TET coil is placed in its pocket, with the cable being
passed to the lower part of the sternotomy incision. The incision
over the TET coil is then closed in layers. The TET coil is placed
before heparinization to decrease the likelihood of a pocket wound
hematoma. A sternal retractor is placed, and a pericardial cradle is
created. Dissection for the internal battery and controller is made
in either the preperitoneal space or deep to the rectus abdominus
muscle (ie, anterior to the posterior rectus sheath). Caval tapes are
placed, and heparin is given. Cannulation of the aorta or femoral
artery is performed depending on the length of aorta available
because many of these patients will have had previous cardiac
surgeries. A superior vena caval cannula is placed, and a femoral
venous cannula is placed and guided up into position just below
the junction of the inferior vena cava and the right atrium. Car-
diopulmonary bypass is initiated, the caval tapes are snared down,
and the aorta is crossclamped. Lidocaine is injected into the
ascending aorta to induce diastolic arrest of the heart. The right and
left ventricles are excised just below the atrioventricular groove,
leaving a small amount of ventricular muscle. The mitral and
tricuspid annuli are preserved, and the valves are excised. The left
atrial appendage is ligated, and the coronary sinus and patent
foramen ovale (if present) are oversewn. The left atrial cuff of the
device is trimmed to appropriate diameter and sewn to the native
left atrium at the level of the annulus by using 2 layers of running
4-0 Prolene sutures reinforced with felt strips. Leak testing is
performed after the creation of each anastomosis to decrease the
likelihood of suture line bleeding or air entrainment after place-
ment of the device. Anastomosis of the right atrial cuff to the
native right atrium is then performed in similar fashion, followed
by leak testing. A cast model of the AbioCor thoracic unit is
positioned in the chest to determine the appropriate length and
orientation of the outflow grafts to the aorta and pulmonary artery.
These outflow grafts are then sewn end to end to the great vessels
with running 4-0 Prolene sutures. The artic outflow graft is posi-
tioned anterior to the pulmonary artery graft. The AbioCor thoracic
unit is then brought up to the operative field, and appropriate
electrical connections are made. The thoracic unit is placed in the
pericardial space and attached to the left atrial cuff and outflow
grafts with snap-lock connectors. Saline is injected into the right
ventricle of the thoracic unit to expedite deairing, and the right
atrial cuff is connected to the device. The caval tapes are released,
and the device is completely deaired by allowing blood and air to
be ejected through the side ports arising from the outflow grafts.
Once the right side of the heart has been deaired, the side port of
the pulmonary artery outflow graft is occluded. The left side of the
heart is then deaired through the side port that arises from the
aortic outflow graft. The device flow is incrementally increased up
to 4 to 5 L/min with the crossclamp on, and all the blood is ejected
through the side port originating from the left outflow graft and
returned to the cardiopulmonary bypass circuit. Once the device is
adequately deaired, the crossclamp is removed, the left side port is
occluded, and the patient is weaned from cardiopulmonary bypass
onto full device support. The left and right filling pressures are
monitored and used to determine the beat rate and to adjust the
TABLE 1. Simplified AbioScore composite variables
A potential candidate must have at least 6 of the criteria listed
in A or at least 4 of the criteria listed in B or C. These factors
are combined with the patient’s age to determine 30-day
survival.
A. 1) More than one continuous intravenous inotrope
2) An intra-aortic balloon pump or other form of
mechanical support
3) Mean arterial pressure 58 mm Hg
4) LVEF 16%
5) CVP between 10 and 18 mm Hg or prothrombin time
between 17 and 25 seconds
6) Abnormal lactate level
7) Serum sodium level 133 mEq/L
8) Urine output 30 mL/h
9) Serum creatine level 3.0 mg/dL
10) Acute renal failure
B. 1) Patient meets UNOS criteria for status 1A
2) Body mass index 20 kg/m2
3) Arterial pH 7.30
4) WBC  17,000
5) Requires support on mechanical ventilator
6) Glasgow Coma Scale score 12
C. 1) Previous heart surgery
2) Ischemic heart disease or chronic rejection after heart
transplant
3) Exercise maximal oxygen consumption of 14 mL · kg1
· min1 or 6-min walk 200 m
4) QRS duration 110 ms or presence of permanent
pacemaker or AICD
5) Left ventricular end-diastolic diameter index 4.0 cm/m2
or severe mitral regurgitation
6) NYHA Class IV 80% of the time for past 6 mo
7) Norephinephrine level 900 ng/L or TNF- 50 ng/L
8) AST 310 U/L or CK 2000 U/L
LVEF, Left ventricular ejection fraction; CVP, central venous pressure;
UNOS, United Network for Organ Sharing; WBC, white blood cell count;
AICD, automatic implantable cardioverter defibrillator; NYHA, New York
Heart Association; TNF, tumor necrosis factor; AST, aspartate aminotrans-
ferase; CK, creatine kinase.
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balance chamber. Protamine is administered after demonstrating
adequate hemodynamics. The sternal edges are approximated.
Transesophageal echocardiography is used to determine whether
sternal closure impairs flow in the left pulmonary veins. Increased
pulmonary vein flow velocity dictates the need to reposition the
thoracic unit caudad, anterior, or both. This is readily accom-
plished by placing sutures through the eyelets on the thoracic unit
and around the left lower ribs. Irrigation with topical antibiotics is
performed, followed by standard wound closure. Prophylactic in-
travenous antibiotics are given per each center’s protocol. The anes-
thetic management for these patients has been previously described.14
Anticoagulation Management
Anticoagulation has been achieved with antiplatelet therapy and
heparin, followed by warfarin. Routine monitoring has been with
assessment of platelet aggregation, partial thromboplastin time,
and the international normalized ratio. The goal of therapy is to
maintain an international normalized ratio of between 2.5 and 3.5.
Some centers have also used daily thromboelastograms and with
this approach have attempted to maintain a normal coagulation
index.
Results
Seven patients have been implanted with the AbioCor IRH
System. All were male, with an age range of 51 to 79 years.
Six of the 7 patients had ischemic and 1 had idiopathic
cardiomyopathy. Four patients had previous bypass surgery,
with one patient having had 3 prior bypass operations. All
patients were inotrope dependent. Five patients had preex-
isting renal dysfunction, and 3 had preexisting liver dys-
function. Three patients were not considered transplant can-
didates because of age (70 years), 4 were excluded
because of increased pulmonary vascular resistance, and 2
patients had significant renal dysfunction. The AbioScore
predicted a 30-day mortality of greater than 89% in 6
patients and 75% in 1 patient. Body surface area ranged
from 1.83 to 2.17 m2. Cardiopulmonary bypass times
ranged from 125 to 240 minutes.
The first recipient was a 59-year-old man with ischemic
cardiomyopathy. He was not a transplant candidate because
of increased transpulmonary gradient and chronic renal dys-
function. The operative procedure was uneventful. He was
explored for bleeding early after the operation, and on
postoperative day 6, a partial dehiscence of the abdominal
wall fascia developed that required exploration and closure.
This patient was not able to tolerate anticoagulation with
heparin or warfarin because of recalcitrant gastrointestinal
bleeding. This patient did tolerate antiplatelet therapy, and
therefore the initial anticoagulation was with dipyridamole
and aspirin. As a result of the gastric bleeding, the aspirin
was stopped, and the patient was started on clopidigrel.
Thromboelastograms were performed daily and demon-
strated that the patient was consistently hypercoagulable on
this limited anticoagulation regimen. Multiple attempts
were made to restart warfarin, and by the third postoperative
month, this was achieved without further gastric bleeding.
During the first 60 days after the operation, the patient was
only receiving antiplatelet therapy 80% of the time. He had
steady improvement in his level of activity and was able to
take more than 20 trips out of the hospital. He had a
transient ischemic attack on postoperative day 61 and a
large cerebrovascular accident on postoperative day 130.
The patient had a large retroperitoneal hemorrhage after his
anticoagulation was increased after his stroke. This resulted
in multiple system organ failure and death on postoperative
day 151.
The second recipient was a 70-year-old man with isch-
emic cardiomyopathy. He was not a transplant candidate
because of age and renal dysfunction. The operative proce-
dure was uneventful, and he had an uncomplicated initial
postoperative course. He was extubated early after the op-
eration but had to be reintubated for recurrent aspirations,
which were documented on video swallowing studies. Be-
cause of recurrent aspiration, the patient underwent trache-
ostomy on postoperative day 40. This patient had 2 episodes
of high fever without evidence of infection. The first epi-
sode was related to vancomycin and resolved when this
drug was discontinued. The second febrile episode resulted
in a temperature of 107.1°F, with rapid onset of anuric renal
failure and markedly increased liver function test results. A
diagnosis of malignant neuroleptic syndrome was made,
and the patient was started on dantrolene, with normaliza-
tion of his temperature within 7 hours. After this febrile
episode, the patient required a brief period of hemodialysis,
followed by complete recovery of renal function. The pa-
tient continued to show progressive improvement and was
eventually discharged from the hospital on postoperative
day 182 and discharged to home on postoperative day 209.
The third recipient was a 68-year-old man with ischemic
cardiomyopathy. He was not a transplant candidate because
of pulmonary hypertension with a high transpulmonary
gradient. The implantation of the AbioCor IRH was un-
eventful. His early postoperative course was remarkable for
the presence of transient liver dysfunction and acute chole-
cystitis, for which he required a cholecystectomy. At the
time of laparotomy, the patient also had a tracheostomy.
The patient also had significant renal dysfunction after the
cholecystectomy that required a period of hemodialysis.
The patient did have complete resolution of his hepatic and
renal function and marked improvement in his functional
status. This recipient had a small cerebrovascular accident
on postoperative day 97, followed by a large cerebrovascu-
lar accident on postoperative day 129. Because of the lack
of neurologic recovery, support was withdrawn on postop-
erative day 142.
The fourth recipient was a 74-year-old man with isch-
emic cardiomyopathy. He was not a transplant candidate
because of age. The recipient had multiple previous cardiac
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operations. The implantation was remarkable for the pres-
ence of severe adhesions and early coagulopathy. The pa-
tient did require an early reoperation for bleeding around the
internal battery and from a femoral arterial line. The pa-
tient’s postoperative course was remarkable for the devel-
opment of progressive renal dysfunction, which required
dialysis, and progressive hepatic dysfunction with marked
hyperbilirubinemia. Because of the lack of end-organ re-
covery, support was withdrawn on postoperative day 56.
The patient had no thromboembolic events.
The fifth recipient was a 51-year-old man with idiopathic
cardiomyopathy. He was not a transplant candidate because
of pulmonary hypertension with a high transpulmonary
gradient. He had respiratory failure early after the operation
that did not respond to conventional measures and necessi-
tated the initiation of temporary venovenous extracorporeal
membrane oxygenation support. Echocardiography at the
time of the operation and in the postoperative period dem-
onstrated normal flows in the pulmonary veins. There was
rapid clearing of the chest radiograph and improvement in
lung function that allowed for removal from extracorporeal
membrane oxygenation on the third postoperative day. The
cause of the respiratory failure is not known. The patient
also had renal dysfunction that required hemodialysis from
the second to the eighth postoperative day. This patient did
have complete recovery of end-organ function and was
discharged from the hospital on postoperative day 70. He
was readmitted 20 days later with pneumonia and is cur-
rently hospitalized.
The sixth recipient was a 79-year-old man with ischemic
cardiomyopathy who was not a transplant candidate because
of age. He underwent an uncomplicated implantation with
restoration of normal hemodynamics. The patient had a
profound coagulopathy, which could not be corrected de-
spite aggressive measures. Because of excessive bleeding,
the patient became hypovolemic and entrained air into the
right side of the device. Cardiopulmonary bypass was rein-
stituted, the device was deaired, and the patient was again
weaned from cardiopulmonary bypass. The coagulopathy
could not be corrected, and the patient died early after the
operation.
The seventh recipient was a 61-year-old man with isch-
emic cardiomyopathy who was not a transplant candidate
because of pulmonary hypertension and renal dysfunction.
He underwent an uncomplicated implantation of the device
with restoration of normal hemodynamics. He had profound
coagulopathy and was treated aggressively with cryoprecip-
itate, fresh frozen plasma, and platelets. He had also re-
ceived full-dose aprotinin therapy. Approximately 3 hours
after the operation was completed, the patient had an acute
decrease in the output of the device. Echocardiography
demonstrated thrombus in the native right atrium. The pa-
tient’s chest was reopened and explored with the findings of
thrombus in the native right atrium and pulmonary artery.
Despite all attempts at resuscitation, the patient died in the
operating room. Autopsy confirmed extensive thrombosis of
the pulmonary vasculature and no evidence of deep venous
thrombosis. The device was found to be free of thrombus.
The autopsy findings were believed to be consistent with an
aprotinin reaction.15-17
Actual survival at 30 days after the operation was 71%,
and that at 60 days was 43%. Predicted survival at 30 days
with continued medical therapy alone was 13%.
All the AbioCor systems operated or continue to operate
satisfactorily. The system implanted in the fifth recipient
experienced 3 and 2 skipped beats on 2 separate occasions
on postoperative days 42 and 43, respectively. This was due
to delayed motion of the switching valve of unknown cause.
The system continues to function on postoperative day 181
without any further episodes. All implanted components
have been well tolerated. The balance chamber has allowed
for left-to-right balance in all patients. There have been no
patients with significant hemolysis related to the device.
There have been no device-related infections.
Four patients improved to the point that they were am-
bulatory after the operation. Three patients took multiple
out-of-hospital excursions. Two patients were discharged
from the hospital to a transitional care setting, with one of
those patients discharged to home on postoperative day 209.
Total days on support with the AbioCor system have been
754. The 2 patients currently on support are at postoperative
days 234 and 181. The postoperative course for all patients
is summarized in Table 2.
Autopsies were performed on 3 patients. All 3 patients
had thrombus adjacent to the lateral atrial cuff struts that
were in contact with atrial tissue. The medial atrial struts,
which were adjacent to the atrial septum, were clean of
thrombus. The blood pumps did not contain thrombus.
There was no evidence of infection or significant tissue
injury related to the internal components. The patient who
died from multiple system organ failure demonstrated pre-
existing liver fibrosis caused by chronic passive congestion.
This patient had no evidence of kidney or brain infarcts at
autopsy.
Discussion
The prevalence of heart failure is high and continues to
increase. Current estimates are that heart failure affects
nearly 5 million people in the United States alone, with
projections that disease prevalence will double in the next 5
years.1,2 The aging of the population and advances in pre-
ventive medicine and in the management of hypertension,
acute myocardial infarction, and diabetes have improved
mortality rates from these disorders and contributed to the
increased incidence of heart failure.18 The World Health
Organization reports a similar prevalence of heart failure in
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less affluent countries caused by valve disease and prema-
ture coronary artery disease.19 The economic effect of this
disease is quite significant. The annual expenditure on heart
failure management in the United States approached $38
billion in 1991. Recent estimates for the total cost of heart
failure management in 1999 is well over $50 billion.18,20
The high mortality associated with heart failure is well
established.3 Recent data from the REMATCH trial dem-
onstrated that inotrope-dependent patients with advanced
heart failure who are not transplant candidates have a 75%
1-year mortality.21
The Institute of Medicine has estimated that 60,000
persons could benefit from cardiac replacement therapy.
Currently, heart transplantation is the only approved method
to replace the failing heart. However, the epidemiologic
effect of heart transplantation is quite limited because of the
small number of donor organs. Despite multiple efforts to
increase the number of suitable donors, there has been a
decrease in donor hearts in 3 of the last 4 years. Long-term
survival after transplantation has been limited primarily by
the development of allograft coronary artery disease, which
contributes to the 4% annual mortality in allograft recipi-
ents.4 Recent advances in the field of xenotransplantation
have led to renewed interest in this field. However, large
immunologic hurdles remain, and the demonstration of in-
fection of multiple human cell lines by pig endogenous
retrovirus has raised concerns over transspecies disease
transmission.22,23
Clearly there is a need for the development of alternative
therapies to replace the failing heart. The AbioCor IRH
TABLE 2. Brief summary of clinical course of initial patients
Patient
no.
Implant
date Postoperative course Autopsy Status
1 7/2/01 Early reoperation for bleeding. Unable to tolerate
anticoagulation because of GI bleeding. Tracheostomy
for pulmonary toilet. Slow recovery. Able to take over
20 out-of-hospital trips. TIA POD 61. CVA POD 130.
Psoas muscle bleed with resultant MSOF and death
POD 151.
Thrombus on atrial
struts. Blood
pumps clean.
Deceased
2 9/13/01 Initial uncomplicated recovery. Tracheostomy for
recurrent aspiration. Malignant neuroleptic syndrome
led to acute renal failure. Complete recovery with
dantrolene and temporary dialysis. Slow recovery.
NA Alive and well;
discharged to
home
3 9/26/01 Early reoperation for tamponade. Laparotomy for acute
cholecystitis. Tracheostomy for prolonged ventilatory
support. Liver failure and renal failure that required
dialysis. Both resolved. Slow recovery. Small CVA POD
97. Large CVA POD 128. Support withdrawn at family’s
request POD 142.
Thrombus on atrial
struts. Blood
pumps clean.
Deceased
4 10/17/01 Early reoperation for bleeding around internal battery and
from femoral arterial line. Progressive renal dysfunction
requiring dialysis. Progressive hepatic dysfunction with
marked hyperbilirubinemia. Because of lack of end-
organ recov ery, support withdrawn POD 56. No T-E
events.
Thrombus on atrial
struts. Blood
pumps clean.
Pre-existing liver
fibrosis.
Deceased
5 11/5/01 Early respiratory failure of unknown cause. Required
veno-venous ECMO support  3 days. Tracheostomy
for prolonged ventilatory support. Evacuation of
hematoma battery pocket and TET coil pocket. TIA
POD 56. Slow recovery with hospital discharged POD
70. Readmission for pneumonia POD 90.
NA Alive; hospitalized
for pneumonia
6 11/26/01 Intraoperative death caused by bleeding NA Deceased
7 4/9/02 Early postoperative death caused by pulmonary embolus
or aprotinin reaction
Thrombus in native
right atrium,
pulmonary
arteries: Blood
pumps clean.
Deceased
GI, Gastrointestinal; TIA, transient ischemic attach; POD, postoperative day; CVA, cerebrovascular accident; MSOF, multiple systems organ failure; NA, not
applicable; T-E, thromboembolism; TET, transcutaneous energy transfer.
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System has been in development for decades and has been
designed for destination therapy. This system has been
designed to be totally implantable without the need for
percutaneous lines or percutaneous access. Energy transfer
across the skin is readily accomplished with inductive cou-
pling. Placement of the internal TET coil in the infraclavic-
ular fossa has resulted in excellent patient comfort and
minimal episodes of misalignment of the internal and ex-
ternal TET coils. An atrial balance chamber that allows for
a decrease in right-sided stroke volume has eliminated the
need for a compliance chamber and allowed for normal
left-to-right balance in all of the recipients. This balance
mechanism is one of the significant advances in the design
of the device. Manipulation of the device beat rate, motor
speeds, and the balance chamber allows for complete con-
trol of the circulation from the time the patient is weaned
from CPB. The balance chamber has also allowed for rapid
manipulation of the left atrial filling pressure, which has
been clinically useful when patients have had pulmonary
vascular congestion.
One major consideration in all clinical trials is determi-
nation of the appropriate patient population. In this trial all
patients must be inotrope dependent and have a predicted
mortality at 30 days of greater than 70%. Also, patients
must not be acceptable candidates for other therapies, in-
cluding transplantation. As a result, we have selected a very
ill cohort of patient, and this has greatly contributed to the
postoperative convalescence. One example of this is the fact
that all recipients have required tracheostomy for prolonged
ventilatory support. This has not been related to the device
per se but rather to the preoperative condition of the recip-
ients. Successful completion of this trial might allow for
evaluation of this device in patients in a less-debilitated
state.
All recipients of the AbioCor artificial heart must have
severe biventricular failure. A number of patients were
screened for this trial and found to have isolated left ven-
tricular failure and were therefore not considered acceptable
candidates. Right ventricular dysfunction was defined by
means of standard echocardiographic evaluation and clini-
cal evidence of right-sided heart failure. The number of
patients with end-stage heart failure who require biventricu-
lar replacement versus left-sided support alone is not
known. This trial and other trials with left ventricular assist
devices as destination therapy might contribute to an under-
standing of the need for univentricular versus biventricular
support. Clearly there continues to be significant morbidity
and mortality related to right ventricular dysfunction, as
evidenced by the recent report from Kavarana and associ-
ates24 describing a 42.8% mortality in left ventricular assist
device recipients who have significant postoperative right
ventricular dysfunction. Our clinical impression is that a
consistent and normal cardiac output combined with imme-
diate lowering of the right-sided filling pressures that we
have seen with the AbioCor IRH has contributed to the
reversal of end-organ dysfunction.
Patient selection has also been based on prediction of
appropriate fit with the AbioFit virtual fit evaluation. Po-
tential candidates undergo computed tomography of the
chest, with the digital files then being entered into the
AbioFit software imaging system developed by ABIOMED.
This allows for a 3-dimensional reconstruction of the chest,
with implantation of the AbioCor thoracic unit in the ap-
propriate orthotopic position. The anatomic relationship of
the thoracic unit with surrounding structures can then be
viewed from every possible angle. This is a powerful tool
that we have become reliant on for selection of patients with
appropriate chest dimensions. We have also found the use of
transesophageal echocardiography to be invaluable at the
time of chest closure to ensure that there is no compression
of the left pulmonary veins. Increased pulmonary vein flow
velocities were seen in 2 patients at sternal closure, which
led to repositioning of the device in a caudad direction with
normalization of flow velocities.
There have been multiple morbidities in this patient
population, as described above. Three of the 5 patients who
survived the early operative period have died, with 2 of
these deaths related to stroke. Autopsies in these 2 patients
revealed thrombus on the left atrial struts that were in
contact with the lateral wall of the left atrium. These struts
were placed on the atrial cuffs during the early animal
implantations in which fitting of the device had yet to be
optimized to avoid collapse of the small bovine atrium by
this active fill device. There was no thrombus related to the
presence of struts in the animal model. These findings have
resulted in the removal of the atrial struts for the next series
of clinical implantations. The absence of the atrial struts will
hopefully result in an acceptably low level of thromboem-
bolism events without leading to problems with inflow to
the device. There was no evidence of infection or significant
tissue injury related to the device components.
In summary, the AbioCor system is the first totally
implantable replacement heart. Early results from this mul-
ticenter trial have demonstrated excellent function of all
device components. The system has allowed for excellent
patient mobility, with 3 recipients taking out-of-hospital
excursions and 2 patients being discharged from the hospi-
tal. This multicenter clinical trial is currently ongoing at 6
sites.
References
1. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of
heart failure: rationale for preventive strategies and comprehensive
disease management. Am Heart J. 1997;133:703-12.
2. Cowie MR, Wood DA, Coats AJS, Thompson SG, Suresh V, Poole-
Wilson PA, et al. Survival of patients with a new diagnosis of heart
failure: a population-based study. Heart. 2000;83:505-10.
Dowling et al Surgery for Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 127, Number 1 139
A
CD
3. Stewart S, MacIntyre K, Hole D, Capewell S, McMurray J. More
‘malignant’ than cancer? Five-year survival following a first admission
for heart failure. Eur J Heart Failure. 2001;3:315-22.
4. UNOS Critical Data. U.S. facts about transplantation. Available at:
http://www.unos.org/newsroom/critdata_main.htm. Accessed April
23, 2002.
5. Dowling RD, Etoch SW, Stevens KA, Johnson AC, Gray LA. Current
status of the AbioCor Implantable Replacement Heart. Ann Thorac
Surg. 2001;71(suppl):S147-9.
6. Dowling RD, Etoch SW, Stevens K, Butterfield A, Koenig SE, John-
son AJ, et al. Initial experience with the totally implantable AbioCor
replacement heart at the University of Louisville. ASAIO J. 2000;46:
579-81.
7. Parnis S, Yu LS, Ochs BD, Macris MP, Frazier OH, Kung RT. Chronic
in vivo evaluation of an electrohydraulic total artificial heart. ASAIO J.
1994;40:M489-93.
8. Kung RT, Ochs BD, Singh PI. A unique left-right flow balance
compensation scheme for an implantable total artificial heart. ASAIO J.
1989;35:468-70.
9. Kung RT, Yu LS, Ochs B, Parnis S, Frazier OH. An atrial hydraulic
shunt in a total artificial heart. A balance mechanism for the bronchial
shunt. ASAIO J. 1993;39:M213-7.
10. Pantalos GM, Reeves C, Dowling RD, Gray LA. Long-term fixation of
external parts of implantable circulatory support systems. ASAIO J.
2002;48(2):158.
11. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley
JD, et al. Early revascularization in acute myocardial infarction com-
plicated by cardiogenic shock. SHOCK Investigators. Should we
emergently revascularize occluded coronaries for cardiogenic shock.
N Engl J Med. 1999;341(9):625-34.
12. McNair DS, inventor. Decision analysis system and method for eval-
uating patient candidacy for a therapeutic procedure. US Patent 6 533
724. March 18, 2003.
13. Rothstein MA, Anderlik MR. The AbioCor artificial replacement
heart: bioengineering meets bioethics. J Cardiothorac Vasc Anesth.
2002;16:234-9.
14. Theilmeier KA, Pank JR, Dowling RD, Gray LA. Anesthetic and
perioperative considerations in patients undergoing placement of to-
tally implantable replacement hearts. Semin Cardiothorac Vasc
Anesth. 2001;5:335-44.
15. Gitter R, Alivizators P, Capehart J, Ramsay M, Jett GK. Aprotinin and
aortic cannula thrombosis. J Thorac Cardiovasc Surg. 1996;112(2):
537-8.
16. Ray MJ, Marsh NA, Mengerson K. A brief review of studies evalu-
ating the adverse effects of aprotinin therapy in aortocoronary bypass
surgery. Thromb Haemost. 1997;77(5):1038-40.
17. Heindel SW, Mill MR, Freid EB, Valley RD, White GC 2nd, Norfleet
EA. Fatal thrombosis associated with a hemi-Fontan procedure, hep-
arin-protamine reversal, and aprotinin. Anesthesiology. 2001;94(2):
369-71.
18. O’Connell JB. The economic burden of heart failure. Clin Cardiol.
2000;23(suppl III):6-10.
19. Cleland JGF, Khand A, Clark A. The heart failure epidemic: exactly
how big is it? [editorial]. Eur Heart J.. 2001;22:623-6.
20. O’Connell JB, Bristow MR. Economic impact of heart failure in the
United States: time for a different approach. J Heart Lung Transplant.
1994;13:S107-12.
21. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW,
Dembitsky W, et al. Long-term use of a left ventricular assist device
for end-stage heart failure. N Engl J Med. 2001;345:1435-43.
22. Patience C, Takeuchi Y, Weiss RA. Infection of human cells by an
endogenous retrovirus of pigs. Nat Med. 1997;3(3):282-6.
23. Wadman M. FDA turns down moratorium demand on xenotransplants.
Nature. 1998;391(6666):423.
24. Kavarana MN, Pessin-Minsley MS, Urtecho J, Catanese KA, Flannery
M, Oz MC, et al. Right ventricular dysfunction and organ failure in left
ventricular assist device recipients: a continuing problem. Ann Thorac
Surg. 2002;73:745-50.
Discussion
Dr Roland Hetzer (Berlin, Germany). I am most grateful for the
outstanding privilege to comment on this historical milestone
achievement, as presented by Dr Dowling and coscientists.
The totally implantable artificial heart has been a dream of
scientists and surgeons since the 1930s and has been realistically
sought for the last 50 years. This has become a reality, and Dr
Lederman and the ABIOMED Company deserve all our admira-
tion for having pursued and succeeded in this ambitious project.
This might be compared with the first journey of man to the moon
in 1969. The development will certainly continue, just as the
spaceships of today are quite different and much more advanced
than the ones then.
Although 5 of 7 desperately ill patients have died, it should be
kept in mind that no other option for survival was seen for them
and that survival with a total artificial heart of more than 60 days
was considered a success in the study design. This goal has been
reached by 4 of the 7 patients.
My comments and questions go to 5 topics.
First, many patients with end-stage heart failure can now be
well treated with left ventricular assist devices, with good mobility
and quality of life. In fact, among the 650 patients who have
received assist devices at my institution, complete cardiac recovery
has been observed in more than 40 with myocarditis and cardio-
myopathy with subsequent removal of the device, and 25 have
been placed on such devices permanently—with the Berlin Heart,
the Novacor, the DeBakey MicroMed, and the Arrow Lion
Heart—for up to more than 3 years.
There is, however, a proportion of patients who require biven-
tricular support, and I would like to ask Dr Dowling what he thinks
the proportion of patients might be who can only be handled with
a total artificial heart?
Second, thrombosis, thromboembolism, and anticoagulation
complications account for 3 of the 5 deaths. Technical improve-
ments have already been undertaken by the company to diminish
this problem. Several of the ventricular assist devices had great
benefit from heparin coating of the inner surfaces. My question is,
what are the plans for the near future to improve on the thrombo-
genicity of the AbioCor?
Third, some parts of the AbioCor might be subject to wear and
exhaustion. In one of our patients with a Lion Heart, the control
system had to be exchanged after 16 months. My question is, what
is the estimated lifetime of the various parts of the AbioCor, and
how can their need for replacement be anticipated to not endanger
the patients?
Fourth, in the various assist devices we have seen different and
distinct alterations of vascular regulation, both humoral and neural.
What are the reactions of peripheral circulation and their sequelae
in the case of a total pulsatile artificial heart?
Finally, long-term substitution of the heart must go along with
a high degree of quality of life for the patient. How does the
AbioCor comply with this demand? That means noise, perceptible
device motion, and anxiety and depression of the patient. Again, I
feel highly honored to be selected to comment on this event, and
I would like to congratulate Dr Dowling, the responsible surgeons,
and the ABIOMED Company on this achievement.
Dr Dowling. Thank you very much for your kind comments.
Let me just jump to the questions and try to give a succinct answer.
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The first question was one I hear quite often: What percentage
of patients will need to be supportive of the total artificial heart? I
do not think any of us really know the answer to that question yet.
I think this trial and ongoing trials, especially with left ventricular
assist devices as destination therapy, will help answer that ques-
tion. I can tell you that once this device is placed, you have
complete control of the circulation. You can adjust the central
venous pressure and the left atrial pressure to be whatever you
want and the cardiac output to be whatever you want. It seems,
from talking to all the investigators, our clinical impression is that
this has resulted in a significant decreased incidence of renal
dysfunction and hepatic dysfunction and has been very much
responsible for getting these patients through the operation and
through the immediate postoperative period.
There was a recent article with which I am sure a lot of you are
familiar from Columbia by Yoshi Naka that demonstrated that
there is still significant morbidity and mortality related to right
ventricular dysfunction after left ventricular assist device place-
ment, and in that experienced center, the mortality from significant
right ventricular dysfunction was 43%. Therefore hopefully this
and other center’s trials with other devices will define the need for
univentricular versus biventricular support.
The second question is related to the incidence of thromboem-
bolic events. The thing that has already been done, as you men-
tioned and as was mentioned in the talk, was removal of the atrial
struts. I do want to emphasize that the blood pumps were entirely
cleaned and at explant looked identical as before implantation. I do
not know of any plans in terms of heparin coating of the device. I
think hope for the next series of implants is that removal of these
struts will have a favorable effect on the incidence of thromboem-
bolic events.
The estimated lifetime of various parts is not known entirely.
The in vitro trials were initiated in April 2000, with a limited
number of devices placed then and some devices placed approxi-
mately 1 year later. The hydraulic membrane appears to last at
least a year, probably longer. The centrifugal pump and the switch-
ing valve, which are essentially the only 2 moving parts of the
energy convertor, I would guess to have an estimated lifespan in
the 3- to 5-year range or longer, but I might be speaking a little bit
out of turn because I do not have the hard data on those.
The effects of the peripheral circulation, interestingly, is that
the patients have a normal pulse, they have a normal pulmonary
artery pressure wave form, and they have normal left and right
atrial pressure wave forms. We have not been able to discern any
abnormal effects of the artificial heart on the peripheral circulation.
The device is noiseless; you cannot hear the device unless you
place a stethoscope or you plant your ear on the chest of one of
these recipients. Last Thursday, I forgot to see one of my patients
in the office, and I remarked that I am used to being able to hear
the patients with left ventricular assist devices when they are here.
But the patients with total artificial hearts, you cannot hear their
devices at all, even if you are standing right next to them. There is
very little motion of the device itself. As you saw from the video
clip, there is alternate motion of the hydraulic fluid to the left and
right, but the device itself has very little motion. With our limited
experience, the patients have not had any excessive anxiety re-
garding the function of the device. As I mentioned in the talk, it
has been very user friendly, and the patients and their families have
rapidly adapted to using all the components.
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